Literature DB >> 16643530

Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001-2004.

I Paraskakis1, D A Kafetzis, A Chrisakis, H Papavasilliou, H Kirikou, A Pangalis, L S Tzouvelekis, T Athanasiou, N J Legakis.   

Abstract

Pneumococci (n = 1033) isolated in the major paediatric hospitals of Athens during 2001-2004 from children with invasive infections (n = 186), non-invasive infections (n = 641) and healthy carriers (n = 206) were studied. The most prevalent serotypes were serotypes 14 (44.6%), 19F (43.5%) and 6B (22.8%) in invasive, non-invasive and carriage isolates, respectively. Among invasive isolates, the potential coverage by the seven-valent conjugate vaccine was 75.3%. Resistance rates to penicillin, amoxycillin, cefotaxime, erythromycin, co-trimoxazole, clindamycin, tetracycline and chloramphenicol were 44.6%, 2.7%, 1.2%, 43.6%, 43.5%, 12.4%, 34.7% and 5.9%, respectively. The M-phenotype accounted for 68.0% of the erythromycin-resistant isolates. All isolates were susceptible to ofloxacin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16643530     DOI: 10.1111/j.1469-0691.2006.01383.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine.

Authors:  S Maraki; G Samonis; E Galanakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-10       Impact factor: 3.267

2.  Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece.

Authors:  Ioanna N Grivea; Alexia Sourla; Eleni Ntokou; Denise C Chryssanthopoulou; Alexandra G Tsantouli; George A Syrogiannopoulos
Journal:  BMC Infect Dis       Date:  2012-10-11       Impact factor: 3.090

3.  The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.

Authors:  Stefan Flasche; Olivier Le Polain de Waroux; Katherine L O'Brien; W John Edmunds
Journal:  PLoS Comput Biol       Date:  2015-04-16       Impact factor: 4.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.